Search results
Results from the WOW.Com Content Network
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending ...
Yahoo Finance Live examines Regeneron Pharmaceuticals' stock following reports of positive results in its eye treatment drug trials.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
Would a stock split help lead Regeneron Pharmaceuticals shares higher? Skip to main content. Subscriptions; Animals. Business. Entertainment. Fitness. Food. Games ... News. Science & Tech.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Regeneron reported an adjusted profit of $11.56 per share on total revenue of $3.55 billion for the quarter, above analysts' estimates of $10.61 per share and $3.38 billion, according to LSEG data.
For premium support please call: 800-290-4726 more ways to reach us